Kbe T, Witte AV, Schnelle A, et al
Tuttle, MD, FASN, FACP, FNKF, executive director for research at Providence Health Care and professor of medicine in the nephrology division at the Institute of Translational Health Sciences at the University of Washington, wrote that the novel concept of combining a glucose-dependent insulinotropic polypeptide with a GLP-1 receptor agonist takes incretin therapeutic agents to a new level. In principle, treatment with a glucose-dependent insulinotropic polypeptide and a GLP-1 receptor agonist together would augment glucose lowering while providing defense against hypoglycemia, Tuttle wrote
Duration should be individualised with your doctor based on your response and goals
The prior authorization requires documentation of the diagnosis, which may include an A1c level, fasting glucose, BMI, etc
Long-acting GHRH preparations may benefit patients with intact pituitary GH secretory capability. (4) Similarly, Ipamorelin has also been suggested to potentially increase hGH synthesis
